Zymeworks Inc. (ZYME)
Zymeworks Statistics
Share Statistics
Zymeworks has 69.58M shares outstanding. The number of shares has increased by -2.4% in one year.
| Shares Outstanding | 69.58M |
| Shares Change (YoY) | -2.4% |
| Shares Change (QoQ) | -3.05% |
| Owned by Institutions (%) | 3.11% |
| Shares Floating | 67.3M |
| Failed to Deliver (FTD) Shares | 80 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 4.56M, so 6.62% of the outstanding shares have been sold short.
| Short Interest | 4.56M |
| Short % of Shares Out | 6.62% |
| Short % of Float | 6.85% |
| Short Ratio (days to cover) | 7.88 |
Valuation Ratios
The PE ratio is -9.05 and the forward PE ratio is -8.46. Zymeworks's PEG ratio is 0.
| PE Ratio | -9.05 |
| Forward PE | -8.46 |
| PS Ratio | 14.55 |
| Forward PS | 3.5 |
| PB Ratio | 0 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0 |
Enterprise Valuation
Zymeworks Inc. has an Enterprise Value (EV) of 584.65M.
| EV / Earnings | -4.77 |
| EV / Sales | 7.66 |
| EV / EBITDA | 0 |
| EV / EBIT | -4.26 |
| EV / FCF | -0.01 |
Financial Position
The company has a current ratio of 3.4, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.4 |
| Quick Ratio | 3.4 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 5.17 |
| Cash Flow / Debt | -5.96 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -0.04%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -0.04% |
| Revenue Per Employee | $272,514.29 |
| Profits Per Employee | $-438,196.43 |
| Employee Count | 280 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 6.08M |
| Effective Tax Rate | -0.05 |
Stock Price Statistics
The stock price has increased by 14.23% in the last 52 weeks. The beta is 1.13, so Zymeworks's price volatility has been higher than the market average.
| Beta | 1.13 |
| 52-Week Price Change | 14.23% |
| 50-Day Moving Average | 13.97 |
| 200-Day Moving Average | 12.32 |
| Relative Strength Index (RSI) | 41.66 |
| Average Volume (20 Days) | 507.08K |
Income Statement
In the last 12 months, Zymeworks had revenue of 76.3M and earned -122.69M in profits. Earnings per share was -1617.67.
| Revenue | 76.3M |
| Gross Profit | 76.3M |
| Operating Income | -137.11M |
| Net Income | -122.69M |
| EBITDA | -137.11B |
| EBIT | -137.11M |
| Earnings Per Share (EPS) | -1617.67 |
Balance Sheet
The company has 66.1B in cash and 18.48B in debt, giving a net cash position of 47.63B.
| Cash & Cash Equivalents | 66.1B |
| Total Debt | 18.48B |
| Net Cash | 47.63B |
| Retained Earnings | -830.34B |
| Total Assets | 463.09M |
| Working Capital | 212.16M |
Cash Flow
In the last 12 months, operating cash flow was -110.04B and capital expenditures 0, giving a free cash flow of -110.04B.
| Operating Cash Flow | -110.04B |
| Capital Expenditures | 0 |
| Free Cash Flow | -110.04B |
| FCF Per Share | -1450.87 |
Margins
Gross margin is 100%, with operating and profit margins of -179.69% and -160.8%.
| Gross Margin | 100% |
| Operating Margin | -179.69% |
| Pretax Margin | -152.82% |
| Profit Margin | -160.8% |
| EBITDA Margin | -179.69K% |
| EBIT Margin | -179.69% |
| FCF Margin | -144.22K% |
Dividends & Yields
ZYME does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13173.21% |
| FCF Yield | -12879.62% |
Analyst Forecast
The average price target for ZYME is $18.5, which is 50.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.5 |
| Price Target Difference | 50.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 1.3 |
| Piotroski F-Score | 3 |